Opus Genetics, Inc. (IRD)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| License and collaborations revenue | 2,882 | 4,370 | 3,867 | |
| Research and development | 6,022 | 7,953 | 8,982 | |
| General and administrative | 5,766 | 6,346 | 2,894 | |
| Total operating expenses | 11,788 | 14,299 | 11,876 | |
| Loss from operations | -8,906 | -9,929 | -8,009 | |
| Fair value change in warrant and other derivative liabilities | 917 | 2,805 | - | |
| Financing costs | -35 | 1,372 | - | |
| Other income, net | 534 | 302 | 483 | |
| Loss before income taxes | -7,420 | -8,194 | -7,526 | |
| Benefit (provision) for income taxes | - | - | - | |
| Net loss | -7,420 | -8,194 | -7,526 | |
| Other comprehensive loss, net of tax | - | - | - | |
| Comprehensive loss | -7,420 | -8,194 | -7,526 | |
| Basic (in dollars per share) | -0.12 | -0.24 | -0.29 | |
| Basic (in shares) | 63,376,392 | 33,884,920 | 26,145,080 | |
| Diluted (in dollars per share) | -0.12 | -0.24 | -0.29 | |
| Diluted (in shares) | 63,376,392 | 33,884,920 | 26,145,080 | |